The new trial, which enrolled more than 1,000 participants across the U.S. and Australia and has an 85-month follow-up plan, will evaluate the effectiveness of combining pembrolizumab, an immunotherapy drug, with the personalized mRNA vaccine V940.
V940 trains the immune system to attack proteins called neoantigens that are specific to a patient’s tumor and is based on a sequence researchers do of the tumor. It can target up to 34 neoantigens.
The previous phase 2b trial showed promising results, according to a March 26 system news release.
At the Becker's Perioperative Summit, taking place October 29–31 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
